Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet oncology Vol. 20; no. 3; pp. 371 - 382
Main Authors:	Loi, Sherene, Giobbie-Hurder, Anita, Gombos, Andrea, Bachelot, Thomas, Hui, Rina, Curigliano, Giuseppe, Campone, Mario, Biganzoli, Laura, Bonnefoi, Hervé, Jerusalem, Guy, Bartsch, Rupert, Rabaglio-Poretti, Manuela, Kammler, Roswitha, Maibach, Rudolf, Smyth, Mark J, Di Leo, Angelo, Colleoni, Marco, Viale, Giuseppe, Regan, Meredith M, André, Fabrice, Fumagalli, Debora, Gelber, Richard D, Goulioti, Theodora, Hiltbrunner, Anita, Hui, Rita, Roschitzki, Heidi, Ruepp, Barbara, Boyle, Fran, Stahel, Rolf, Aebi, Stefan, Coates, Alan S, Goldhirsch, Aron, Karlsson, Per, Kössler, Ingrid, Fournarakou, Stamatina, Gasca, Adriana, Pfister, Rita, Ribeli-Hofmann, Sabrina, Weber, Magdelena, Celotto, Daniela, Comune, Carmen, Frapolli, Michela, Sánchez-Hohl, Magdalena, Huang, Hui, Mahoney, Caitlin, Price, Karen, Scott, Karolyn, Shaw, Holly, Fischer, Susan, Greco, Monica, King, Colleen, Andrighetto, Stefania, Piccart-Gebhart, Martine, Findlay, Heather, Jenkins, Michelle, Karantza, Vassiliki, Mejia, Jaime, Schneier, Patrick
Format:	Journal Article Web Resource
Language:	English
Published:	England Elsevier Ltd 01-03-2019 Elsevier Limited Lancet Publishing Group
Subjects:	Apoptosis Biopsy Breast cancer Cancer therapies Cell death Clinical trials Data processing Drug dosages Dyspnea Effusion ErbB-2 protein Human health sciences Hypertension Immunotherapy Intravenous administration Ligands Lymphocytes T Metastases Metastasis Monoclonal antibodies Oncologie Oncology Paraffin Patients PD-1 protein PD-L1 protein Pembrolizumab Pneumonitis Respiration Sciences de la santé humaine Targeted cancer therapy Toxicity Trastuzumab Tumors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, added to trastuzumab in trastuzumab-resistant, advanced HER2-positive breast cancer. We did this single-arm, multicentre, phase 1b–2 trial in 11 centres based in five countries. Eligible participants were women aged 18 years or older, who had advanced, histologically confirmed, HER2-positive breast cancer; documented progression during previous trastuzumab-based therapy; an Eastern Cooperative Oncology Group performance status of 0 or 1; and a formalin-fixed, paraffin-embedded metastatic tumour biopsy for central assessment of programmed cell death 1 ligand 1 (PD-L1) status. In phase 1b, we enrolled patients with PD-L1-positive tumours in a 3 + 3 dose-escalation of intravenous pembrolizumab (2 mg/kg and 10 mg/kg, every 3 weeks) plus 6 mg/kg of intravenous trastuzumab. The primary endpoint of the phase 1b study was the incidence of dose-limiting toxicity and recommended phase 2 dose; however, a protocol amendment on Aug 28, 2015, stipulated a flat dose of pembrolizumab of 200 mg every 3 weeks in all Merck-sponsored trials. In phase 2, patients with PD-L1-positive and PD-L1-negative tumours were enrolled in parallel cohorts and received the flat dose of pembrolizumab plus standard trastuzumab. The primary endpoint of the phase 2 study was the proportion of PD-L1-positive patients achieving an objective response. This trial is registered in ClinicalTrials.gov, number NCT02129556, and with EudraCT, number 2013-004770-10, and is closed. Between Feb 2, 2015, and April 5, 2017, six patients were enrolled in phase 1b (n=3 received 2 mg/kg pembrolizumab, n=3 received 10 mg/kg pembrolizumab) and 52 patients in phase 2 (n=40 had PD-L1-positive tumours, n=12 had PD-L1-negative tumours). The data cutoff for this analysis was Aug 7, 2017. During phase 1b, there were no dose-limiting toxicities in the dose cohorts tested. Median follow-up for the phase 2 cohort was 13·6 months (IQR 11·6–18·4) for patients with PD-L1-positive tumours, and 12·2 months (7·9–12·2) for patients with PD-L1-negative tumours. Six (15%, 90% CI 7–29) of 40 PD-L1-positive patients achieved an objective response. There were no objective responders among the PD-L1-negative patients. The most common treatment-related adverse event of any grade was fatigue (12 [21%] of 58 patients). Grade 3–5 adverse events occurred in 29 (50%) of patients, treatment-related grade 3–5 adverse events occurred in 17 (29%), and serious adverse events occurred in 29 (50%) patients. The most commonly occurring serious adverse events were dyspnoea (n=3 [5%]), pneumonitis (n=3 [5%]), pericardial effusion (n=2 [3%]), and upper respiratory infection (n=2 [3%]). There was one treatment-related death due to Lambert-Eaton syndrome in a PD-L1-negative patient during phase 2. Pembrolizumab plus trastuzumab was safe and showed activity and durable clinical benefit in patients with PD-L1-positive, trastuzumab-resistant, advanced, HER2-positive breast cancer. Further studies in this breast cancer subtype should focus on a PD-L1-positive population and be done in less heavily pretreated patients. Merck, International Breast Cancer Study Group.
Bibliography:	scopus-id:2-s2.0-85062182506
ISSN:	1470-2045 1474-5488 1474-5488
DOI:	10.1016/S1470-2045(18)30812-X